Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nutritional Neuroscience|December 28, 2017
The relationship between dietary quality, serum brain-derived neurotrophic factor (BDNF) level, and the Val66met polymorphism in predicting depressionAmy Froud, Jenifer Murphy, Lachlan Cribb, et al.
Nutritional Neuroscience|May 30, 2017
Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in CaucasiansLachlan Cribb, Jenifer Murphy, Amy Froud, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-AnalysesJerome Sarris, Jenifer Murphy, David Mischoulon, et al.
The American Journal of Psychiatry|April 27, 2016
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-AnalysesJerome Sarris, Jenifer Murphy, David Mischoulon, et al.
Journal of Integrative Medicine|February 8, 2024
Predictors of the placebo response in a nutraceutical randomized controlled trial for depressionRosemary Arnold, Jenifer Murphy-Smith, Chee H Ng, et al.
CNS Drugs|September 17, 2015
N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled StudyJerome Sarris, Georgina Oliver, David A Camfield, et al.
Trials|November 4, 2015
Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trialKaren M Savage, Con K Stough, Gerard J Byrne, et al.
Journal of Psychiatric Research|December 24, 2018
L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trialJerome Sarris, Gerard J Byrne, Lachlan Cribb, et al.
European Journal of Nutrition|September 27, 2019
EPA and DHA as markers of nutraceutical treatment response in major depressive disorderKiki P van der Burg, Lachlan Cribb, Joseph Firth, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 18, 2018
Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial<sup/>Jerome Sarris, Gerard J Byrne, Chad Bousman, et al.
Pageof 2